Key facts
- Harbinger Health’s last known valuation is $520.0M (Sep 2023).
- It has raised $290.0M; the latest was Later Stage VC ($100.0M) in Jan 2025.
- Notable investors include Partners Investment, Modi Ventures, Flagship Pioneering, Pictet, Catalyst Housing Group — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Harbinger Health
- ·The full record, as it builds
Funding rounds
No funding rounds for Harbinger Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Harbinger Health
Developer of an AI-enabled blood-based cancer detection platform designed to identify cancers in a pre-disease state and reduce cancer-related uncertainty for clinicians and patients. The company offers proprietary blood-based tests, AI-driven biological analysis, and advanced screening technologies, enabling underserved individuals facing healthcare disparities to access early, affordable cancer detection.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2020
- Employees
- 65
- Website
- harbinger-health.com/
- Ownership
- Privately Held (backing)
Harbinger Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Harbinger Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Harbinger Health in its N-PORT filings yet. We sweep new filings monthly.